Drugs / NKG001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07617779 | Apr 2024 → Apr 2028 expected | spinal muscular atrophy | Nikegen Pharmaceutical (Hangzhou) Company Limited | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NKG001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07617779 ↗ |
| Route | Intrathecal | “via combined intravenous and intrathecal routes” NCT07617779 ↗ |
| Route | Intravenous | “via combined intravenous and intrathecal routes” NCT07617779 ↗ |